OptimizeRx Corp. (NASDAQ:OPRX) Sees Significant Growth in Short Interest

OptimizeRx Corp. (NASDAQ:OPRX) saw a significant growth in short interest in March. As of March 31st, there was short interest totaling 1,988,505 shares, a growth of 25.0% from the March 15th total of 1,590,947 shares. Approximately 11.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 563,519 shares, the short-interest ratio is presently 3.5 days.

OptimizeRx Trading Up 2.9%

NASDAQ:OPRX traded up $0.19 during trading hours on Thursday, hitting $6.59. 290,799 shares of the company were exchanged, compared to its average volume of 442,229. The stock has a market capitalization of $123.55 million, a price-to-earnings ratio of 25.43 and a beta of 1.28. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a one year low of $5.54 and a one year high of $22.25. The company has a fifty day simple moving average of $7.33 and a 200 day simple moving average of $12.48.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. Sell-side analysts expect that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its Board of Directors has initiated a stock buyback program on Thursday, March 5th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on OPRX shares. B. Riley Financial reiterated a “buy” rating and set a $11.00 price target (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Stephens lowered their price target on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. Roth Mkm lowered their price target on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 6th. Lake Street Capital lowered their price objective on OptimizeRx from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, OptimizeRx presently has an average rating of “Moderate Buy” and a consensus price target of $17.57.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Hillsdale Investment Management Inc. raised its position in OptimizeRx by 10.9% during the 4th quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock worth $249,000 after purchasing an additional 2,000 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in OptimizeRx by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after acquiring an additional 2,188 shares during the period. BNP Paribas Financial Markets grew its holdings in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares during the period. AQR Capital Management LLC grew its holdings in OptimizeRx by 18.4% during the 4th quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock worth $178,000 after acquiring an additional 2,256 shares during the period. Finally, Harbor Capital Advisors Inc. grew its holdings in OptimizeRx by 12.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock worth $305,000 after acquiring an additional 2,708 shares during the period. 76.47% of the stock is owned by institutional investors.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.